|
Real-time
OTC Markets
18:57:58 03/06/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.1052 USD | -2.09% |
|
+5.04% | -87.61% |
| 08-14 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 08-14 | Casi Pharmaceuticals, Inc. Announces Management Changes | CI |
| Market Cap | 2.67M 2.39M 2.19M 1.99M 3.74M 253M 3.81M 26.18M 10.55M 134M 10.04M 9.83M 422M | P/E 2024 |
-1.11x | P/E 2025 | -0.33x |
|---|---|---|---|---|---|
| Enterprise Value | 24.53M 21.9M 20.1M 18.28M 34.27M 2.32B 34.96M 240M 96.75M 1.23B 92.06M 90.1M 3.87B | EV / Sales 2024 |
1.75x | EV / Sales 2025 | 1.9x |
| Free-Float |
53.46% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -2.09% | ||
| 1 week | +5.04% | ||
| Current month | -19.08% | ||
| 1 month | -10.00% | ||
| 3 months | -18.25% | ||
| 6 months | -32.84% | ||
| Current year | -87.61% |
| 1 week | 0.1 |  | 0.13 |
| 1 month | 0.1 | | 0.13 |
| Current year | 0.05 | | 1.2 |
| 1 year | 0.05 | | 1.48 |
| 3 years | 0.05 | | 8.48 |
| 5 years | 0.05 | | 11.7 |
| 10 years | 0.05 | | 88.92 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Cory
CEO | Chief Executive Officer | 62 | 21/07/2025 |
Kun Qian
DFI | Director of Finance/CFO | 44 | 16/05/2025 |
Chun Hua Wang
COO | Chief Operating Officer | 54 | 01/01/2017 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Wu
BRD | Director/Board Member | 62 | 01/04/2013 |
Zhen Bo Su
BRD | Director/Board Member | 50 | 21/03/2023 |
Thomas Folinsbee
BRD | Director/Board Member | 59 | 21/03/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 18/03/26 | Emerging Technology Partners LLC
| Other | Company | 1,097,341 | 7.0830% | |
| 18/03/26 | Panacea Venture
| Other | Company | 4,529,956 | 29.2393% | |
| 18/03/26 | Other | Chief Financial Officer | 75,000 | 0.4841% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.09% | +5.04% | -92.69% | -97.77% | 2.67M | |
| -0.49% | +9.74% | +56.57% | +141.89% | 1,263B | |
| -1.51% | +1.06% | +44.49% | +79.13% | 658B | |
| -2.32% | +0.71% | +36.24% | +101.58% | 521B | |
| -1.54% | +0.18% | +53.06% | +66.79% | 391B | |
| -0.62% | +5.73% | +80.23% | +44.55% | 369B | |
| -1.69% | +3.17% | +32.18% | +55.35% | 307B | |
| -0.72% | +7.83% | +12.10% | +33.76% | 290B | |
| +0.09% | +4.86% | +57.35% | +74.89% | 252B | |
| -0.49% | +7.22% | +39.40% | +109.45% | 212B | |
| Average | -1.17% | +5.31% | +31.89% | +60.96% | 426.19B | |
| Weighted average by Cap. | -1.07% | +6.60% | +48.36% | +92.80% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 28.54M 25.48M 23.38M 21.27M 39.87M 2.7B 40.67M 279M 113M 1.43B 107M 105M 4.5B | 20.71M 18.49M 16.97M 15.44M 28.94M 1.96B 29.52M 203M 81.7M 1.03B 77.73M 76.08M 3.27B |
| Net income | -39.26M -35.05M -32.16M -29.26M -54.85M -3.72B -55.95M -384M -155M -1.96B -147M -144M -6.2B | -48.06M -42.91M -39.37M -35.82M -67.15M -4.55B -68.49M -470M -190M -2.4B -180M -177M -7.58B |
| Net Debt | 6.05M 5.4M 4.96M 4.51M 8.45M 573M 8.62M 59.2M 23.86M 302M 22.71M 22.22M 955M | 21.85M 19.51M 17.9M 16.29M 30.54M 2.07B 31.14M 214M 86.2M 1.09B 82.02M 80.27M 3.45B |
Employees
214
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | $0.1301 | +14.18% | 258 |
| 29/10/26 | $0.1140 | +13.96% | 11,522 |
| 27/10/26 | $0.1000 | -.--% | 252 |
| 26/10/26 | $0.1000 | -0.25% | 640 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CASIF Stock
Select your edition
All financial news and data tailored to specific country editions
